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OBJECTIVE — This study tested a model hypothesizing that treatment affects objective clin-
icaloutcomes,whichinturnaffectperceivedconsequences,whichinturnaffectsatisfactionand
preference judgments.
RESEARCH DESIGN AND METHODS — The model was tested in a double-blind,
randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo
pramlintide to their insulin regimens. Objective clinical outcomes included changes in glucose
and weight control, insulin requirements, incidence of hypoglycemia, and study drug tolerance.
At the end of the trial, patients completed the validated PRAM-TSQ questionnaire measuring
treatment satisfaction and preference and perceived medication beneﬁts and side effects.
RESULTS — Statistical modeling demonstrated that active pramlintide was signiﬁcantly as-
sociated with greater treatment satisfaction, preference, and perceived beneﬁts (all except hy-
poglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial
glucose [PPG], lower medication tolerance, more hypoglycemia). Perceptions of treatment con-
sequences were sensitive and speciﬁc to their cognate objective clinical outcomes (no halo
effects). Clinical outcomes (especially PPG) accounted for almost half of the effect of the study
medicationontreatmentsatisfactionandpreference.Treatmentsatisfactionandpreferencewere
strongly related to the perceived beneﬁts/side effects of the study medication, and these percep-
tions (especially glucose control) mediated most of the association of clinical outcomes with
satisfaction and preference.
CONCLUSIONS — This model received substantial empirical support. Improvements in ob-
jective clinical outcomes accounted for a large part of the association of pramlintide treatment with
highertreatmentsatisfactionandpreference.Perceivedtreatmentconsequencesmediatedtheeffectof
objective clinical beneﬁts on satisfaction with and preference for the study medication.
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A
ssessment of patient-reported out-
comes (PROs), especially treatment
satisfaction, is increasingly recog-
nized as important in determining the ef-
ﬁcacy of new therapies (1,2). Treatment
satisfactionmaybeassociatedwithadher-
ence to treatment (3), glycemic control
(2,4,5), and treatment preference (6).
Most studies of treatment satisfaction and
preference assess differences between
groups using different treatments, but the
diabetes literature reveals little effort to
determine how treatment affects treat-
ment satisfaction and preference. We
have begun to develop a model that con-
ceptualizesthisprocess(Fig.1,toppanel).
Treatment (e.g., initiation of a new med-
ication) affects objective clinical out-
comes (e.g., A1C levels), which in turn
affect perceived consequences (e.g., bet-
ter glucose control, more frequent hypo-
glycemia), which in turn affect treatment
satisfaction(e.g.,beliefthatthebeneﬁtsof
treatmentoutweightheburden)andpref-
erencejudgments(e.g.,desiretocontinue
taking the new medicine). Other per-
ceivedconsequencesoftreatmentthatare
not driven by objective clinical outcomes
(e.g.,convenience,pain,etc.)alsomayin-
ﬂuence satisfaction and/or preference
judgments (7).
Our research has provided prelimi-
nary support for this model. We found
that several objective clinical outcomes
were associated with perceived beneﬁts
(8) and treatment satisfaction and/or
preference (7,9). We also found that
perceived beneﬁts of treatment were
associated with treatment satisfaction/
preference (6,7) and accounted for most
of the difference between groups in treat-
ment satisfaction/preference (6). How-
ever, several key research questions
should be more fully addressed:
1. Do objective clinical outcomes ac-
count for group differences in treat-
ment satisfaction or preference? Just
because a group differs on both types
of factors does not demonstrate that
the factors are necessarily related to
each other; such an assumption is an
example of the “ecological fallacy”
(10,11). Demonstrating the effect of
improved clinical outcomes on PRO
requires that they be linked at the in-
dividual level (i.e., by correlation/
regression analysis) (8). Moreover,
where studies include several clinical
outcomes, it is important to assess the
relative contribution of each outcome
to differences between treatment
groups in satisfaction and preference.
It is important to note that the clinical
outcomemostresponsivetotreatment
isnotnecessarilytheonewiththelarg-
est effect on treatment satisfaction or
preference (6).
2. Howdoobjectiveclinicaloutcomesaf-
fect patients’ subjective perceptions of
treatment consequences (beneﬁts and
side effects)? For example, does an ob-
jective clinical beneﬁt such as weight
reduction give rise to only one speciﬁc
perceived beneﬁt (perceived weight
control), or, as we found earlier (8),
does an objective clinical beneﬁt have
a halo effect and contribute to other
perceived beneﬁts?
3. Do perceived treatment consequences
mediate the relationship between ob-
jective clinical outcomes and treat-
ment satisfaction or preference (e.g.,
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the relationship between objective glu-
cose and treatment satisfaction or pref-
erence?),and,ifso,howmuchdoeseach
perceived consequence contribute to
treatment satisfaction and preference?
We have some evidence regarding the
relative contribution of speciﬁc per-
ceived consequences to treatment satis-
faction/preference (6,7) but not in the
context of a randomized clinical trial
(RCT) and not whether perceived bene-
ﬁts and side effects mediate the relation-
ship of clinical outcomes to satisfaction
and preference.
4. For a particular treatment, are satisfac-
tion with and preference for the treat-
ment differently related to the various
objective clinical outcomes and per-
ceivedconsequencesoftreatment,orare
these two PROs interchangeable?
5. Does treatment satisfaction mediate
the relationship of the various objec-
tive clinical outcomes and perceived
treatment consequences with treat-
ment preference, or do some per-
ceived consequences have direct
relationships with preference?
The current report examines the pro-
posed model in the context of a study of
patientswithtype1diabetesparticipating
inanRCTcomparingtheeffectsofadding
pramlintide or placebo with patients’ in-
sulinregimen.Thisstudyiswellsuitedfor
testing our model because 1) the RCT de-
sign allows us to be conﬁdent that the
observed group differences are a result of
the study medication rather than uncon-
trolled factors, and 2) the study medica-
tion (pramlintide, an analog of human
amylin) is hypothesized to effect multiple
clinical outcomes, including lower A1C
and postprandial glucose (PPG) levels,
weight reduction compared with taking
insulin alone, and reduced doses of meal-
time insulin (12,13). Pramlintide also has
some potential drawbacks; it requires an
injection before each meal in addition to
the patient’s insulin regimen (14), and its
useisassociatedwithgastrointestinalside
effects,includingnausea,insomepatients
(15,16).
This study incorporates both objec-
tive and subjective measures of all these
potential treatment effects, thereby per-
mitting an analysis of the interrelation-
ships among these factors and their
association with treatment satisfaction
and preference. The PRO measure (9,17)
was designed to assess perceived clinical
sideeffectsandbeneﬁtsofthestudymed-
ication, as well as overall judgments of
satisfaction and preference. The instru-
ment did not assess some of the more tra-
ditional determinants/components of
treatment satisfaction (e.g., convenience,
comfort), which are less central to the
proposed model.
RESEARCH DESIGN AND
METHODS— A total of 266 adults
with type 1 diabetes completed the 29-
week, double-blind, placebo-controlled,
multicenter trial. A full description of the
Figure1—Associationsamongmodelelements:objectiveclinicaloutcomes,perceivedtreatmentconsequences,treatmentsatisfaction,andtreatment
preference. Only paths with signiﬁcant standardized regression coefﬁcients from Table 2 are shown. Direct paths from treatment arm to PROs are
not shown in order to simplify the diagram.
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exclusion criteria, medication, self-
monitored blood glucose regimen, and
data collection procedures, can be found
elsewhere (12). The study protocol was
approved by an institutional review
board, and all participants provided writ-
teninformedconsentbeforeparticipating
in the trial. The study was conducted in
accordancewiththeprinciplesoftheDec-
laration of Helsinki (1964), including all
amendmentsthroughtheSouthAfricare-
vision (1996).
Clinical measures
Clinical parameters assessed at baseline
and at the end of the trial were daily total
insulindose,weight,A1C,andPPG(mea-
sured as the average of the daily averages
over 2 weeks). Diary data were used to
obtain the measures of PPG and insulin
dose. Also measured were hypoglycemia
and study medication dose (pramlintide
orplacebo).Hypoglycemiaincidencewas
the natural log of the actual number of
events (taken after adding one to the
number to correct for the log of zero).
Severe hypoglycemia incidence was a bi-
nary yes/no (1/0) measure deﬁned using
the Diabetes Control and Complications
Trial criteria (18). Study medication dose
wasabinaryyes/no(1/0)variableindicat-
ing whether the participant was able to
take the maximum (60 g/meal) dose.
PRO measures
PROs were assessed at the end of the trial,
with the double-blind protocol still in
place, using a 14-item questionnaire, the
PRAM-TSQ (9,17). Response options
were on a 6-point Likert scale from strong
agreement with the item (scored 6) to
strong disagreement (scored 1), with equal
increments between response options.
PRO measures included several indi-
vidualitemsmeasuringspeciﬁcperceived
beneﬁts of the study medication (items
1–5: perceptions of blood glucose con-
trol,ﬂexibleeating,weightcontrol,hypo-
glycemia prevention, and appetite
control, respectively) and absence of side
effects (item 6 with reverse scoring). Two
multi-item scales were calculated as the
means of their constituent items: treat-
ment satisfaction (items 7–12: percep-
tions of beneﬁts greater than insulin
alone, less worries about having diabetes,
moreconﬁdencemanagingdiabetes,ben-
eﬁts that outweighed the burden of extra
injections, improved ability to function,
feeling better overall) and treatment pref-
erence (items 13 and 14: desire to con-
tinue taking the study medication and
willingness to recommend it to others).
Reliability was adequate for the two
multi-item scales: treatment satisfaction
(0.92)andtreatmentpreference(
0.69).
Statistical analysis
Onlythe263caseswithcompletedatafor
all PRO measures were included in the
analysis. The last-observation-carried-
forward method was used for missing
data on the clinical outcome measures.
For all variables with missing data after
using these techniques, we assigned par-
ticipantsthemeanvalueofthatvariablein
theirtreatmentarm.Theonlyclinicalout-
comesforwhichmorethanonevaluewas
imputed were PPG (n  39) and insulin
dose (n  52).
The model’s hypothesized indepen-
dent associations among treatment
group, clinical outcomes, perceived con-
sequences, satisfaction, and preference
were assessed with hierarchical ordinary
least squares (OLS) regression using
forced entry (19,20). The ﬁrst block of
variables included respondent character-
istics, baseline values of clinical out-
comes, and treatment arm. The second
block of variables included the measures
of objective clinical outcomes. For the
analyses of treatment satisfaction and
preference,thethirdblockofvariablesin-
cluded perceived consequences of the
study medication. Finally, in the analysis
of treatment preference, treatment satis-
faction was entered in the ﬁnal block to
assess whether it made an additional
contribution to explanatory power and
mediated the association of treatment
preference with other explanatory
variables.
Note that clinical outcomes and per-
ceived consequences can affect satisfac-
tion or preference even though they are
not related to treatment arm; these asso-
ciations account for within-treatment-
group variation rather than between-
treatment-group variation. Only factors
related both to treatment assignment and
to satisfaction or preference can mediate
the effect of treatment assignment on sat-
isfaction or preference.
RESULTS
Baseline characteristics
Study participants were mostly white
(93%),female(55%),andusingcontinuous
subcutaneous insulin infusion (54%). Re-
spondents were middle-aged ([means 
SD] 41.1 13.2 years) and had diabetes of
long duration (20.2  11.9 years). Partici-
pants were somewhat overweight (81.4 
17.3 kg) and in suboptimal glycemic con-
trol (PPG  185.9  38.3 mg/dl; A1C 
8.1  0.8%). Total daily insulin dose was
substantial (55.128.1 units). There were
no statistically signiﬁcant differences be-
tween the treatment arms at baseline (re-
sults not shown).
Objective clinical outcomes and
perceived treatment consequences
differed by treatment group
A precondition for assessing our concep-
tualmodelwastheexistenceofsigniﬁcant
treatment arm differences in clinical out-
comes, perceived treatment conse-
quences, satisfaction, and preference.
Table1presentstheanalysesofgroupdif-
ferences in objective clinical outcomes
and PROs demonstrating that these pre-
conditions were met. For clinical out-
comes, the placebo medication arm
experienced signiﬁcantly less hypoglyce-
mia during the trial, and more placebo
participantswereabletotoleratethemax-
imum dosage of study medication. The
active medication arm experienced statis-
tically signiﬁcant advantages in two ob-
jective clinical outcomes: weight and
PPG. There were no signiﬁcant differ-
ences for A1C or insulin requirements.
The pramlintide arm had a statisti-
cally signiﬁcant advantage for all PRO
measures except hypoglycemia preven-
tion and absence of side effects; not sur-
prisingly, those taking placebo reported
lowersideeffects.Forthesixmeasureson
which there was a statistically signiﬁcant
beneﬁt for the active medication, four of
the effect sizes (glucose control, weight
control, appetite control, and treatment
satisfaction)mettheone-halfSDcriterion
for a “minimally detectable difference”
(21), the criterion representing a “moder-
ate” effect (22).
Clinical outcomes were associated
with perceived beneﬁts and side
effects
Althoughnoneoftheperceivedtreatment
consequences were associated with
changeinA1Corinsulinrequirements,as
hypothesized, each perceived conse-
quencewasassociatedwithacorrespond-
ing clinical outcome (see Table 2A–F).
Improved postprandial glucose levels
wereassociatedwithbetterperceivedglu-
cose control and ﬂexibility in eating, im-
proved weight was associated with better
perceived weight and appetite control,
Peyrot and Rubin
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ated with better perceived hypoglycemia
prevention, and ability to tolerate the
maximal pramlintide dose was associated
with fewer perceived side effects. These as-
sociations demonstrate the sensitivity/
responsiveness of the perception of
beneﬁts/sideeffectstoobjectiveclinicalout-
comes. The associations also manifested
content speciﬁcity; no patient assessment
was signiﬁcantly associated with an objec-
tive clinical outcome to which it did not
correspond.
Clinical outcomes were associated
with treatment satisfaction and
preference
Independent associations of treatment
satisfaction and preference with clinical
outcomes (controlling for baseline mea-
sures) are presented in Table 2. Higher
treatment satisfaction was associated with
improved PPG (see model TS1). Higher
preference for the study medication was as-
sociated with improved PPG and reduced
insulin requirements (see model TP1).
Objective clinical outcomes partially
mediated the relationship between
treatment group and PROs
Of seven PRO measures for which there
were statistically signiﬁcant differences
between treatment arms, introduction of
objective clinical outcomes into the mod-
els accounted for 20–49% (median 
46%) of the PRO difference (compare
each  in Table 1 to the corresponding 
for treatment arm in Table 2, models A–F,
TS1, TP1) (see Fig. 1 for a representation of
all mediations). Four of ﬁve signiﬁcant as-
sociations between treatment arm and per-
ceived consequences remained signiﬁcant
after controlling for clinical outcomes.
Perceived treatment consequences
mediated the association of objective
clinical outcomes with treatment
satisfaction and preference
Perceived glucose control and ﬂexibility
of eating were associated with higher
treatment satisfaction and mediated the
association of PPG change with treatment
satisfaction (compare model TS1 to
model TS2). Perceived glucose control
alsowasassociatedwithtreatmentprefer-
ence and mediated the association of PPG
change with preference (compare model
TP1 to model TP2). Introduction of per-
ceived consequences did not mediate the
signiﬁcant association of treatment pref-
erence with change in insulin require-
ments (see model TP2).
Treatment satisfaction mediated the
association of perceived beneﬁts
with treatment preference
Treatment satisfaction mediated the asso-
ciation of treatment preference with per-
ceived glucose control but not with
perceived side effects or objective change
in insulin requirements (see model TP3).
Sensitivity analyses performed using data
for which missing values were not im-
puted revealed no meaningful differences
in results compared with those reported
here for the imputed data.
CONCLUSIONS — The purpose of
this study was to test a model of objective
and subjective determinants of treatment
satisfaction and preference, speciﬁcally
that treatment affects objective clinical
outcomes, which in turn affect per-
ceived consequences, which in turn
affect satisfaction and preference judg-
ments. The results of our analyses are
illustrated in Fig. 1.
The results show that the study med-
ication raises treatment satisfaction by re-
ducingpostprandialglucoselevels,which
increases perceived glucose control and
ability to eat ﬂexibly. The effect of im-
proved postprandial glucose and per-
ceived glucose control on treatment
preference is mediated by treatment satis-
faction, which outweighs the negative ef-
fect of lowered medication tolerance and
perceived side effects. Reduction of insu-
lin dose makes an independent contribu-
tion to increased preference for the study
medication but does not contribute to the
treatment group difference in medication
preference.
The results illustrated in Fig. 1 ad-
dress the research questions identiﬁed
Table 1—End of the trial measures by treatment group
Active
pramlintide
Placebo
pramlintide
Unadjusted effect
size (, SDU)
Adjusted effect
size (, SDU)
n 129 134
Clinical outcomes
Log number of hypoglycemic events 3.67  1.09 3.40  1.04 0.12*, 0.25 0.15*, 0.28
Severe hypoglycemic event 27.1% 13.4% 0.13*, 0.28 0.17†, 0.34
Maximal pramlintide dose 72.1% 93.3% 0.28‡, 0.55 0.29‡, 0.58
Change in insulin requirement (units/day) 0.59  74.04 4.76  34.34 0.04, 0.07 0.04, 0.07
Change in weight (kg) 1.60  3.80 1.28  2.94 0.39‡, 0.79 0.40‡, 0.81
Change in A1C (%) 0.38  0.86 0.45  0.85 0.04, 0.08 0.03, 0.06
Change in PPG (mg/dl) 38.27  39.18 7.40  38.25 0.37‡, 0.74 0.35‡, 0.71
Patient reported outcomes
Glucose control 4.18  1.44 3.15  1.65 0.32‡, 0.63 0.34‡, 0.67
Flexible eating 3.42  1.53 2.89  1.63 0.17†, 0.33 0.20†, 0.39
Weight control 3.70  1.74 2.33  1.41 0.40‡, 0.80 0.41‡, 0.83
Appetite control 4.00  1.71 2.63  1.53 0.39‡, 0.78 0.41‡, 0.82
Hypoglycemia prevention 2.84  1.40 2.72  1.41 0.04, 0.09 0.04, 0.09
Absence of side effects 4.71  1.66 5.31  1.22 0.20‡, 0.41 0.19‡, 0.39
Treatment satisfaction 3.79  1.35 2.83  1.43 0.33‡, 0.65 0.35‡, 0.69
Treatment preference 4.77  1.49 4.22  1.75 0.17†, 0.33 0.17‡, 0.34
Data are means  SD, unless otherwise indicated. Effect sizes for study outcomes were measured by ANOVA with the -statistic (unadjusted) and ANCOVA with
the -statistic (adjusted for race, sex, age, duration of diabetes, multiple daily injections/continuous subcutaneous insulin infusion, and baseline values of insulin,
weight, A1C, and PPG), as well as by the difference between treatment groups in SD units (SDU). *P  0.05; †P  0.01; ‡P  0.001.
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the individual-level clinical outcomes
(hypoglycemia, pramlintide dose, change
in postprandial and long-term glucose
levels, weight, and insulin required) ac-
counted for almost half of the effect of the
study medication on perceptions of treat-
ment consequences and judgments of
treatmentsatisfactionandpreference.Im-
proved postprandial glucose had the
strongest effect on treatment satisfaction
and preference; lowered insulin require-
ments also had a signiﬁcant effect on
preference.
Second, our results showed that the
effects of objective clinical factors on spe-
ciﬁc perceived beneﬁts and side effects
were as hypothesized (each measure of
perceived consequences was signiﬁcantly
associatedwiththeparticularclinicalout-
come to which it corresponded [sensitiv-
ity] and only with that outcome
[speciﬁcity]). For the one perceived con-
sequence (glucose control) with two rele-
vant clinical outcomes (changes in A1C
and PPG), only PPG had a signiﬁcant in-
dependent association. Elsewhere (8), we
have offered several explanations of this
pattern, including the fact that A1C levels
and changes are not experienced as di-
rectlyorasfrequentlybythepatientasthe
PPGlevelsandchangesrevealedbyblood
glucose self-monitoring, which provides
immediate and powerful feedback to pa-
tients about treatment efﬁcacy compared
withthefeedbackfromA1C,whichisless
frequent and after the fact.
Third, our results showed how vari-
ous perceived treatment consequences
mediate the relationship between objec-
tive clinical outcomes and treatment
satisfaction or preference. Treatment
satisfaction and/or preference were inde-
pendentlyrelatedtoeachoftheperceived
consequences of the study medication,
with perceived improvement in glucose
control having the strongest association
(asmightbeexpectedforanantihypergly-
cemicmedication).Inonebeneﬁtdomain
represented by two relevant measures
(appetite/weight control), only the appe-
tite-control measure was related to treat-
ment satisfaction, perhaps because
appetite control comprises a more fre-
quent, visceral, and immediate subjective
experience than weight control (parallel-
ing the experiential primacy of PPG over
A1C noted above).
Fourth, results showed that, despite
some similarities, treatment satisfaction
and preference for the study medication
were differently related to clinical out-
comes and perceived consequences. Sat-
isfaction was independently related more
to perceived beneﬁts, while preference
was related more to perceived side effects
and objective clinical outcomes.
Finally, we demonstrated that treat-
ment satisfaction mediated the associa-
tion of perceived glucose control with
treatmentpreferenceandproducedasub-
stantial increment to explanatory power.
The latter ﬁnding suggests that either the
measure of treatment satisfaction incor-
porates unmeasured treatment conse-
quences, or it represents synergistic
effects of measured factors. Interestingly,
treatment satisfaction did not mediate the
relationship between perceived absence
of side effects and preference. Our earlier
research (9) indicated that perceptions of
side effect absence and treatment beneﬁts
do not cluster together, and these results
demonstratethatitisimportanttoretaina
separate measure of perceived side effects
because it may play an important role in
treatment preference.
Research implications
The model investigated here can provide
a foundation for future research. For ex-
ample, controlling for clinical outcomes
did not eliminate all treatment arm differ-
ences in perceived consequences, treat-
ment satisfaction, or preference. This
indicates that patients’ subjective percep-
tions and judgments about treatment are
more complex than our empirical model
(e.g., perceived hypoglycemia prevention
did not mediate the effect of reducing in-
sulin dose, implicating negative percep-
tions of insulin beyond hypoglycemia
risk) (23); these should be studied in fu-
ture research. Relatedly, this study did
not capture all the potential perceived
consequences that might be relevant to
patients’ judgments about treatment sat-
isfaction and preference. Perhaps unmea-
suredperceivedconsequencesthatdonot
have a corresponding objective clinical
outcome (e.g., convenience, comfort/
pain, safety, etc.) would account for addi-
tional variance or some of the variance
now attributed to the measured conse-
quences (6,7); these factors should be in-
corporated into future tests of this model.
Finally, we do not know whether the fac-
tors in this model would have the same
inﬂuence with different medications; re-
search with other medications should in-
clude measures of the speciﬁc objective
and perceived effects of those medica-
tions. Analysis of PROs in studies of a
treatment intervention should analyze
each perceived consequence separately to
obtain a unique perceived risk/beneﬁt
proﬁle for that intervention.
Clinical implications
Our ﬁndings suggest that patients recog-
nize the objective clinical beneﬁts and
side effects of their treatments and that
they are especially likely to recognize
those that are most immediate (e.g.,
changes in PPG rather than changes in
A1C; changes in appetite rather than
changes in weight). Our ﬁndings also
suggest that perceived beneﬁts are pow-
erfully associated with treatment satis-
faction, which is related to treatment
adherence (4) and clinical outcomes
(2,5,6). Clinicians should consider help-
ing patients identify immediate, percepti-
ble beneﬁts of prescribed treatments and
heightenthesalienceofthesebeneﬁtsasa
means to improve treatment adherence,
treatment satisfaction, and clinical out-
comes (23). In addition, the ﬁnding that
treatment satisfaction did not mediate the
relationship between perceived absence
of side effects and treatment preference
suggests that patients’ concerns about
side effects should be addressed speciﬁ-
cally in order to enhance treatment
adherence.
Limitations
Our model hypothesizes causal pathways
from perceived consequences to satisfac-
tion and preference. However, all data for
these pathways were collected at the end
of the study, and these relationships are
cross-sectional. Without knowing the
temporal dynamics of these associations,
we cannot conﬁdently assert causal path-
ways. Moreover, the study population is
not necessarily representative; patients
whoenrollinRCTstendtodifferfromthe
general patient population. Thus, the
generalizability and validity of the results
may be limited. Finally, the study medi-
cationhasaparticulareffectproﬁlethat,if
known to patients, may have signiﬁcantly
inﬂuenced their perceptions, satisfaction,
and preferences and might not be present
in other studies.
Summary
This report developed a model that iden-
tiﬁes objective and subjective determi-
nants of treatment satisfaction and
preference and the linkages among them.
The model states that treatment affects
objectiveclinicaloutcomes,whichinturn
affect perceived consequences, which in
turn affect satisfaction and preference
How treatment satisfaction works
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stantial empirical support and per-
formed reasonably well in accounting
for treatment satisfaction and prefer-
ence. Additional research will be re-
quiredtofurtherdevelopthemodeland
determine its generalizability.
Acknowledgments— Preparation of this
manuscript was funded by Amylin Pharma-
ceuticals, which also provided access to the
data. No other potential conﬂicts of interest
relevant to this article were reported.
The authors were responsible for all analy-
ses and all aspects of manuscript preparation,
includinginterpretationofresults.Nomedical
writers assisted in the preparation of this
manuscript.
References
1. FoodandDrugAdministration.Guidance
for industry: patient-reported outcome
measures: use in medical product devel-
opment and labeling claims. Available
at http://www.fda.gov/cder/guidance/
5460dft.pdf. Accessed 24 March 2008
2. Marra G, the DIAB.&TE.S Project Study
Group. The DIAB. &TE.S Project: how
patients perceive diabetes and diabetes
therapy. Acta Biomed 2004;75:164–170
3. Charpentier G, Fleury F, Dubroca I, Vaur
L, Clerson P. Electronic pill-boxes in the
evaluation of oral hypoglycemic agent
compliance. Diabetes Metab 2005;31:
189–195
4. Kelley K, Dempsey C. An evaluation of an
insulin transfer programme delivered in a
group setting. J Clin Nurs 2007;16:152–
158
5. TahraniAA,DigwoodS,LeeC,MoulilkP.
Evaluation of glargine group-start ses-
sions in patients with type 2 diabetes as a
strategy to deliver the service. Int J Clin
Pract 2007;61:329–335
6. Peyrot M, Rubin RR. Validation and reli-
ability of an instrument for assessing
health-related quality of life and treat-
ment preferences: the Insulin Delivery
System Rating Questionnaire. Diabetes
Care 2005;28:53–58
7. Rubin R, Peyrot M. Quality of life, treat-
ment satisfaction, and treatment prefer-
ence associated with use of a pen device
delivering a premixed 70/30 insulin as-
part suspension (aspart protamine sus-
pension/soluble aspart) versus alternative
treatment strategies. Diabetes Care 2004;
27:2495–2497
8. Rubin RR, Peyrot M. Assessing treatment
satisfaction in patients treated with pram-
lintide as an adjunct to insulin therapy.
Curr Med Res Opin 2007;23:1919–1929
9. Rubin R, Peyrot M. Psychometric prop-
erties of an instrument for assessing
treatment satisfaction associated with
pramlintide use. Diabetes Educ 2009;
35:136–146
10. RobinsonWS.Ecologicalcorrelationsand
the behavior of individuals. Am Sociol
Rev 1950;15:351–357
11. Peyrot M. Modeling psychosocial effects
on glucose control. Diabetes Care 1985;
8:305–306
12. Edelman S, Garg S, Frias J, Maggs DG,
Wang Y, Zhang B, Strobel S, Lutz K,
Kolterman O. A double-blind, placebo-
controlled trial assessing pramlintide
treatment in the setting of intensive insu-
lin therapy in type 1 diabetes. Diabetes
Care 2006;29:2189–2195
13. Hollander PA, Levy P, Fineman MS,
MaggsDG,ShenLZ,StrobelSA,WeyerC,
Kolterman OG. Pramlinitide therapy as
an adjunct to insulin therapy improves
long-term glycemic and weight control in
patients with type 2 diabetes: a 1-year
randomized controlled trial. Diabetes
Care 2003;26:784–790
14. SYMLIN [package insert]. San Diego, CA,
Amylin Pharmaceuticals, 2005
15. Whitehouse F, Kruger DF, Fineman MS,
Shen L, Ruggles JA, Maggs DG, Weyer C,
Kolterman OG. A randomized study and
open-label extension evaluating the long-
term efﬁcacy of pramlintide as an adjunct
to insulin therapy in type 1 diabetes. Di-
abetes Care 2002;25:724–730
16. Ratner RE, Dickey R, Fineman MS, Maggs
DG,StrobelSA,WeyerC,KoltermanOG.
Amylin replacement with pramlintide as
adjunct to insulin therapy improves long-
term glycemic and weight control in type
1 diabetes mellitus: a one-year random-
izedcontrolledtrial.DiabetMed2004;21:
1204–1212
17. DCCT Research Group. Epidemiology of
severehypoglycemiaintheDiabetesCon-
trol and Complications Trial. Am J Med
90:450–459, 1991
18. Marrero DG, Crean J, Zhang B, Kellmeyer
T, Gloster M, Herrmann K, Rubin RR,
Fineberg N, Kolterman O. Effect of ad-
junctive pramlintide treatment on treat-
ment satisfaction in patients with type 1
diabetes. Diabetes Care 2007;30:210–
216
19. Peyrot M. Causal modeling: theory and
applications.JPedPsychol1996;21:3–24
20. PeyrotM,McMurryJ,KrugerD.Abiopsy-
chosocial model of glycemic control in
diabetes: stress, coping and regimen ad-
herence. J Health Soc Behav 1999;40:
141–158
21. Norman GR, Sloan JA, Wyrwich KW. In-
terpretation of changes in health-related
quality of life: the remarkable universality
of half a standard deviation. Med Care
2003;41:582–592
22. Cohen J: Statistical Power Analysis for the
Behavioral Sciences. London, Academic
Press, 1969
23. Peyrot M, Rubin RR, Polonsky WH. Dia-
betesdistressanditsassociationwithclin-
ical outcomes in patients with type 2
diabetes treated with Pramlintide as an
adjuncttoinsulintherapy.DiabetesTech-
nol Ther 2008;10:461–466
Peyrot and Rubin
DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009 1417